STONEGATE SYSTEMSThis is the most-asked question we get from operators, so here is the answer kept current - what actually changed, what the change does and does not mean, and what a store selling either compound still has to do.
The status in three sentences
As of July 2026: BPC-157 is no longer on the FDA's 503A Category 2 list (the "significant safety risk" bucket for compounding), following a February 2026 announcement and an April 2026 removal. It has not been approved, authorized, or added to the 503A bulks list - removal from a negative list is not placement on a positive one. TB-500 (the thymosin beta-4 fragment) was never the subject of the same move and sits exactly where it did before: unapproved, sellable only as a genuine research-use-only chemical, with every FDA warning-letter risk that entails.
If you sell either compound, nothing about your obligations got lighter this year. The intended-use doctrine, the RUO framing, the copy discipline - all of it still applies in full. The rest of this page is the detail.
The timeline: how BPC-157 got here
- September 2023 - Category 2 placement. FDA placed BPC-157 in Category 2 of its interim 503A bulk substances framework, citing safety concerns for compounded use. Category 2 means compounding pharmacies could not use it; it says nothing directly about research chemical vendors, but processors and platforms read it as a red flag and treated it as one.
- 2024-2025 - the enforcement years. BPC-157 shows up by name in FDA warning letters to peptide sellers throughout this period - not because the compound itself was banned to research vendors, but because the sellers' marketing made human intended use obvious. The letters in our warning-letter index cite it repeatedly, always alongside dosing language, benefit claims, or customer-facing "protocols."
- February 2026 - the announcement. FDA announced it would revisit BPC-157's Category 2 placement after reviewing nominations and new data submissions. This is the event most of the "BPC-157 is legal now!" posts trace back to. Read what it actually was: an agency saying it would reconsider a compounding classification.
- April 2026 - the removal. BPC-157 came off Category 2. It was not moved to the 503A bulks list. It entered the review pipeline instead - which brings us to July.
- July 2026 - PCAC. The Pharmacy Compounding Advisory Committee is taking up bulk substance nominations this cycle, BPC-157 among the candidates discussed for potential 503A bulks list inclusion. A PCAC recommendation is advisory; FDA then decides, and that decision historically lands months to years after the meeting.
Removal is not authorization - the distinction vendor pages get wrong
Here is the error we see on live storefronts right now, sometimes in the hero copy: "BPC-157 was removed from the FDA's restricted list - it's now legal." Every clause of that sentence is doing something wrong.
Category 2 was never a list of compounds illegal to sell for research. It was a compounding classification - substances FDA said licensed pharmacies should not compound into preparations for patients. Coming off it means FDA no longer asserts that specific compounding safety concern. It does not mean:
- BPC-157 is FDA-approved. It is not. There is no approved drug product containing it.
- BPC-157 can be marketed for human use. It cannot. An unapproved compound marketed for human use is an unapproved new drug - the exact charge in every peptide warning letter since 2023.
- Your store can relax its RUO posture for this one compound. The intended-use doctrine does not have a per-compound off switch. FDA reads the totality of your site, and a "now legal!" banner is itself evidence of human intended use - you are telling customers the human-use rules changed.
The full framework - what "legal to sell" actually turns on for a research vendor - is in our guide on whether you can legally sell peptides online. The one-line version: the compound's classification matters less than what your website says people should do with it.
The 503A bulks list and the July 2026 PCAC meeting
The 503A bulks list is the positive list - substances licensed compounding pharmacies may use even though no approved drug contains them. Getting on it requires nomination, data review, a PCAC discussion, and a final FDA determination published through rulemaking. That is the track BPC-157 is now on, and the July 2026 PCAC meeting is the next visible step.
Two things operators should understand about this process:
- It is slow and it can go either way. PCAC has recommended against nominated substances before. Even a favorable recommendation then waits on FDA's formal decision. Nobody selling today should build their 2026 plan on a 503A outcome.
- Even the best case does not legalize your storefront's current model. 503A inclusion authorizes licensed pharmacies to compound the substance for individually prescribed patients. It does not authorize a research chemical vendor to market it for human use. Those are different channels with different rules, and the second one is not you.
What this means for your store today
Practically: run in July 2026 exactly as you should have run in July 2025.
- RUO framing on every page - banner, footer disclaimer, qualified-researcher gate, and product copy with zero dosing, zero benefit claims, zero "users report" language. The complete surface list is in the peptide website compliance checklist.
- No status-change marketing. Do not announce the Category 2 removal to customers. A research buyer has no reason to care about a compounding classification - the only audience that copy speaks to is people planning human use, and FDA knows it.
- Watch your imported copy. If your product descriptions came from a supplier datasheet or a competitor, assume they contain claim language. The 2025 letters - including the one we broke down in the Pinnacle Peptides warning letter analysis - cite product-page phrasing that reads like it was pasted in without a second look.
- Processors have not updated their view. Every mainstream processor that prohibited peptide sales before April still prohibits them. Category 2 removal changed zero underwriting policies that we have seen. Plan payments the same way you did in Q1.
If you are not sure whether your current BPC-157 or TB-500 pages would survive an FDA read-through, that is a solvable question - our free 60-second audit scans your live copy against the same claim patterns the warning letters cite. Your domain, sixty seconds, grade on screen.
How gated compounds should be handled: recorded decisions, not vibes
The deeper lesson of the BPC-157 saga is operational. Compound status is not static - it moved in September 2023, February 2026, and April 2026, and it will move again after PCAC. A store that manages this with a mental note and a Discord rumor is one news cycle away from selling something it should not, or panic-pulling something it did not need to.
The durable pattern is a classification system enforced in code: a hard do-not-list the store physically cannot list (GLP-1s, HGH, anything approved or in trials), a gated tier that requires a recorded counsel decision - a date, a name, a note - before it can go live, and an auto-clear tier for everything else. When status changes, one classification record changes, with a paper trail of who decided and why, and the storefront follows. That is how we build every store, because "someone remembered to check" is not a compliance system.
What changes - and what doesn't - if 503A inclusion lands
Say PCAC recommends BPC-157 and FDA eventually adds it to the bulks list. What actually changes for a research vendor?
- Changes: compounding pharmacies get a lawful channel. Regulatory temperature around the compound drops somewhat. Processors may soften over time - they follow FDA's lead with a lag measured in quarters.
- Does not change: your intended-use exposure. An RUO vendor marketing an unapproved compound for human use is committing the same violation the day after inclusion as the day before. The warning letters would keep going to sloppy sites; the compound name in them would just carry a different footnote.
The honest read: 503A inclusion would be good news for the category and nearly irrelevant to your copy discipline. The rules that can kill your store are about what you say, and those are not up for a vote in July.
Questions, answered straight
Is BPC-157 legal to sell in 2026?
As a genuine research-use-only chemical, with a site that supports that framing in every detail - the same qualified yes as before April 2026. Marketed for human use in any way, no, and the Category 2 removal did not move that line an inch.
Did the FDA approve BPC-157?
No. Removal from Category 2 is not approval. There is no approved BPC-157 drug product, and no announcement suggesting one is close. Any vendor page saying "FDA approved" is wrong in a way that invites the exact scrutiny it thinks it escaped.
Is TB-500 in the same position as BPC-157?
No - it is in the older, simpler position. No Category 2 removal, no PCAC review changing its posture. Unapproved substance, RUO-only, cited in warning letters when sellers market it for human use. Its status did not change in 2026.
Can I mention the April 2026 removal on my product page?
You can state a regulatory fact, but ask who the copy is for. A researcher buying a reference standard does not care about compounding classifications - that message targets human-use buyers, and it reads that way to a regulator scoring your site's totality. We tell clients to leave it off. The traffic it wins is the traffic that gets stores flagged.
Will the July 2026 PCAC meeting settle this?
No. PCAC recommends; FDA decides later, often much later. Whatever headline comes out of the meeting, check what actually changed on the 503A lists before changing anything about your store - or let someone whose job is watching this check for you.
This page is general information for store operators, not legal advice. Compound classifications change; for decisions about your specific catalog, talk to counsel.